 Efficacy toxicity thromboxane synthetase inhibitor cerebral vasospasm subarachnoid hemorrhage efficacy possible side effects thromboxane synthetase inhibitor treatment cerebral vasospasm subarachnoid hemorrhage SAH patients grades IV Hunt Hess classification patients underwent aneurysmal clipping hours SAH synthetase inhibitor Cataclot sodium p- phenyl patients continuous drip infusion dose microgram/kg/min days group patients drug group patients group patients symptomatic vasospasm SAH patients transient deterioration consciousness and/or motor disturbance patients mild neurological deficit discharge patient permanent dysphasia hemiparesis result ischemic brain damage due patient side effect hand patients group symptomatic vasospasm patient transient neurological deficit discharge patients permanent neurological deficits independent life discharge patients severe disturbance consciousness ischemia due month onset SAH group Cataclot patients epidural hematoma administration drug patient intracranial pressure complication results synthetase inhibitor effective occurrence symptomatic vasospasm neurological deterioration due SAH drug hazardous side effect tendency death patients